Orphazyme ADS holders given July deadline
After July 11, the Bank of New York Mellon can choose to sell the underlying shares.
by mikkel aabenhus hemmingsen, translated by catherine brett
The owners of Orphazyme’s American Depository Shares (ADSs), which are evidenced by American Depository Receipts (ADRs), must contact the Bank of New York Mellon, which owns the underlying shares, before July 11, the firm writes in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
.jpg)
Orphazyme CEO on sale: "It’s sad, but we tried everything"
For subscribers
Orphazyme reports USD 90m deficit for 2021
For subscribers
.jpg&w=384&q=75)
